vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $9.3M, roughly 1.4× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -13.2%, a 13.8% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -3.0%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 16.1%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
LSF vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $9.3M |
| Net Profit | $-1.8M | $58.0K |
| Gross Margin | 34.1% | 61.8% |
| Operating Margin | -13.5% | 5.3% |
| Net Margin | -13.2% | 0.6% |
| Revenue YoY | 15.0% | -3.0% |
| Net Profit YoY | -341.4% | 101.3% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $9.3M | ||
| Q3 25 | $12.9M | $6.9M | ||
| Q2 25 | $12.0M | $7.7M | ||
| Q1 25 | $11.7M | $6.8M | ||
| Q4 24 | $11.6M | $9.6M | ||
| Q3 24 | $11.8M | $8.8M | ||
| Q2 24 | $10.0M | $8.4M | ||
| Q1 24 | $9.9M | $6.8M |
| Q4 25 | $-1.8M | $58.0K | ||
| Q3 25 | $-975.1K | $-1.6M | ||
| Q2 25 | $-362.2K | $-2.6M | ||
| Q1 25 | $-156.2K | $-2.1M | ||
| Q4 24 | $-398.4K | $-4.6M | ||
| Q3 24 | $-166.1K | $-2.1M | ||
| Q2 24 | $-239.1K | $-91.0K | ||
| Q1 24 | $-1.0M | $-3.4M |
| Q4 25 | 34.1% | 61.8% | ||
| Q3 25 | 36.5% | 60.4% | ||
| Q2 25 | 39.9% | 56.2% | ||
| Q1 25 | 41.9% | 53.5% | ||
| Q4 24 | 38.6% | 61.4% | ||
| Q3 24 | 43.0% | 60.1% | ||
| Q2 24 | 41.8% | 59.0% | ||
| Q1 24 | 40.0% | 45.6% |
| Q4 25 | -13.5% | 5.3% | ||
| Q3 25 | -7.7% | -16.9% | ||
| Q2 25 | -3.3% | -30.1% | ||
| Q1 25 | -1.9% | -25.0% | ||
| Q4 24 | -4.1% | -44.7% | ||
| Q3 24 | -2.3% | -18.2% | ||
| Q2 24 | -3.4% | -5.7% | ||
| Q1 24 | -11.0% | -42.7% |
| Q4 25 | -13.2% | 0.6% | ||
| Q3 25 | -7.6% | -23.4% | ||
| Q2 25 | -3.0% | -33.6% | ||
| Q1 25 | -1.3% | -31.2% | ||
| Q4 24 | -3.4% | -47.6% | ||
| Q3 24 | -1.4% | -23.6% | ||
| Q2 24 | -2.4% | -1.1% | ||
| Q1 24 | -10.3% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.62 | ||
| Q1 25 | — | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | — | $-0.51 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $11.5M | $2.9M |
| Total Assets | $19.2M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $7.9M | ||
| Q3 25 | $5.1M | $7.1M | ||
| Q2 25 | $3.9M | $6.0M | ||
| Q1 25 | $7.0M | $6.5M | ||
| Q4 24 | $8.3M | $7.3M | ||
| Q3 24 | $7.9M | $7.1M | ||
| Q2 24 | $7.6M | $5.5M | ||
| Q1 24 | $7.1M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $11.5M | $2.9M | ||
| Q3 25 | $12.8M | $1.3M | ||
| Q2 25 | $13.4M | $532.0K | ||
| Q1 25 | $13.3M | $3.0M | ||
| Q4 24 | $13.2M | $5.0M | ||
| Q3 24 | $13.1M | $9.4M | ||
| Q2 24 | $12.6M | $9.5M | ||
| Q1 24 | $12.7M | $9.4M |
| Q4 25 | $19.2M | $30.5M | ||
| Q3 25 | $18.9M | $30.7M | ||
| Q2 25 | $20.4M | $29.5M | ||
| Q1 25 | $21.5M | $33.0M | ||
| Q4 24 | $19.3M | $34.9M | ||
| Q3 24 | $18.8M | $39.4M | ||
| Q2 24 | $18.0M | $38.8M | ||
| Q1 24 | $17.6M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $-239.0K | ||
| Q3 25 | $1.2M | $-64.0K | ||
| Q2 25 | $-2.8M | $-1.9M | ||
| Q1 25 | $-1.3M | $-550.0K | ||
| Q4 24 | $339.2K | $703.0K | ||
| Q3 24 | $305.8K | $-302.0K | ||
| Q2 24 | $642.7K | $591.0K | ||
| Q1 24 | $-422.3K | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
